EMA's CHMP Adopts Negative Opinion on Arimoclomol for Niemann-Pick Disease Type C

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion regarding the marketing authorization for Arimoclomol, a treatment for Niemann-Pick Disease Type C. This decision impacts Zevra Therapeutics, the developer of the drug.